Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with histologically confirmed, adenocarcinoma of the colon or rectum (mCRC)~* Subjects with KRAS wild-type status of tumour tissue~* Chemotherapy naïve subjects~* Subject who have signed written informed consent (as per institutional protocol)~Exclusion Criteria:~* As per summary of product characteristics of cetuximab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).